Key result
Palliative NSCLC radiotherapy is linked to ~7% thoracic toxicity hospitalization, predicted by higher esophageal dose.
Why the study?
Palliative radiotherapy or chemoradiotherapy for NSCLC may cause severe thoracic toxicities leading to hospitalization or death in the acute and sub-acute phases, but risk factors are not well defined.
Cohort (n=165)
No
Palliative radiotherapy or chemoradiotherapy for NSCLC has a satisfactory safety profile in the acute phase, with hospitalization risk primarily driven by esophageal radiation dose.
Supports palliative RT safety in advanced NSCLC; leaves open prospective validation of esophageal dose constraints.
INTRODUCTION: Palliative radiotherapy or chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) may cause thoracic toxicities due to the radiation dose delivered to the lungs, heart, and esophagus. We studied severe thoracic toxicities resulting in hospitalization or death during the acute and sub-acute phase, i.e., three months from commencing radiotherapy. In addition, risk factors were identified. Methods: A retrospective review of 165 patients treated with three-dimensional conformal palliative radiotherapy or CRT was performed. The prescribed total dose was equivalent to at least 30 Gy in 10 fractions. Uni- and multivariate analyses were employed. RESULTS: Twelve patients (7%) were hospitalized within three months from the start of radiotherapy or CRT. Six patients were hospitalized for esophagitis, three for dyspnea most likely caused by pneumonitis, and three for cardiac arrhythmia. Fatal toxicity was not observed. However, 19% of the 165 patients died from tumor-related causes during the time period of interest. In multivariate analysis, the only esophageal dose was significantly associated with the risk of hospitalization. Conclusion: The safety profile of palliative radiotherapy or CRT in the acute and subacute phases was satisfactory. The hospitalization rate can be reduced by lowering the esophageal dose, as long as safe lung and heart doses can be maintained.
No takes yet. Share an insight, caveat, or question.
Nieder et al. (2021) conducted a cohort in Non-Small Cell Lung Cancer (n=165). Palliative radiotherapy or chemoradiotherapy was evaluated on Hospitalization for thoracic toxicity within 3 months. Palliative radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer resulted in a 7% rate of hospitalization for thoracic toxicity within three months, with higher mean esophageal dose significantly predicting hospitalization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: